KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astrana Health (ASTH) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Astrana Health (ASTH) over the last 11 years, with Q3 2025 value amounting to $670000.0.

  • Astrana Health's Gains from Investment Securities rose 5895.05% to $670000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 193883.61%. This contributed to the annual value of $388545.0 for FY2024, which is 2294.46% down from last year.
  • Per Astrana Health's latest filing, its Gains from Investment Securities stood at $670000.0 for Q3 2025, which was up 5895.05% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Astrana Health's Gains from Investment Securities peaked at $18.5 million during Q4 2023, and registered a low of $27000.0 during Q1 2021.
  • Its 5-year average for Gains from Investment Securities is $1.9 million, with a median of $387000.0 in 2022.
  • In the last 5 years, Astrana Health's Gains from Investment Securities plummeted by 9748.65% in 2021 and then surged by 1858484.85% in 2023.
  • Over the past 5 years, Astrana Health's Gains from Investment Securities (Quarter) stood at $238000.0 in 2021, then plummeted by 58.4% to $99000.0 in 2022, then surged by 18584.85% to $18.5 million in 2023, then crashed by 95.6% to $814000.0 in 2024, then dropped by 17.69% to $670000.0 in 2025.
  • Its last three reported values are $670000.0 in Q3 2025, $1.4 million for Q2 2025, and $5.7 million during Q1 2025.